Skip to main content

Posts

Showing posts with the label gene therapy

Groundbreaking Gene Therapy Enables Deaf Baby to Hear: A New Era in Audiology

One Step Closer In Medical Breakthrough   In a medical breakthrough, a toddler born deaf due to a rare genetic condition can now hear without any external aids, thanks to pioneering gene therapy. Opal Sandy, an 18-month-old from the U.K., has become the youngest recipient of this transformative treatment, sparking hope for similar advancements in treating congenital hearing loss. Diagnosed at just three weeks old with auditory neuropathy, Opal's condition is a rare form of hearing loss where the ears detect sound, but the brain does not receive the signals. This is due to mutations in the OTOF gene, which is crucial for the protein otoferlin to facilitate communication between the inner ear and brain neurons. When Opal was 11 months old, she became part of a groundbreaking global trial that aimed to correct this genetic defect. This trial involved administering a modified virus to deliver a functional copy of the OTOF gene directly into the cells of her right ear. The gene therapy ...

Experimental Gene Therapy Restores Some Vision In Patients With Inherited Blindness

A breakthrough CRISPR trial brings light to those living in darkness, restoring vision in patients with a rare genetic condition. For Olivia Cook, a 22-year-old college student at Missouri State University, the world had always been a blur, confined to the narrow tunnel of her limited central vision. Born with Leber congenital amaurosis (LCA), Cook experienced life as if peering through a pinhole. However, her visual reality began to change dramatically following her participation in a groundbreaking clinical trial that employed CRISPR, a cutting-edge gene-editing technology, to treat her inherited retinal disorder. The phase 1/2 clinical trial, spearheaded by a collaboration of leading U.S. institutions including Mass Eye and Ear, Perelman School of Medicine at the University of Pennsylvania, and others, aimed to correct mutations responsible for inherited retinal degenerations—a leading cause of blindness globally. The trial marked a significant milestone as it was the first to use t...